At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RVMD Revolution Medicines, Inc.
Not Yet Opened 10-08 16:00:00 EDT
188.12
-12.75
-6.35%
盘后188.60
+0.48+0.26%
19:58 EDT
High199.64Low180.49Vol4.86M
Open198.51D1 Closing200.87Amplitude9.53%
Mkt Cap40.32BTradable Cap34.80BTotal Shares214.34M
T/O903.35MT/O Rate2.63%Tradable Shares185.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

RBC would be buyers of Revolution Medicines after FDA docs ‘overreaction’
TIPRANKS  ·  03:45
RBC would be buyers of Revolution Medicines after FDA docs ‘overreaction’
Revolution Medicines selloff ‘overdone and misguided,’ says TD Cowen
TIPRANKS  ·  03:40
Revolution Medicines selloff ‘overdone and misguided,’ says TD Cowen
Revolution Medicines Falls on Pancreatic Cancer Drug Data Concerns
Reuters  ·  02:17
Revolution Medicines Falls on Pancreatic Cancer Drug Data Concerns
Revolution trading down after daraxonrasib review docs, says Stifel
TIPRANKS  ·  00:05
Revolution trading down after daraxonrasib review docs, says Stifel
Movement Alert｜Revolution Medicines, Inc. Falls 5.28% in Regular Trading, Biotech Sector Weakness Pressures Shares
Market Focus  ·  10-08 21:58
Movement Alert｜Revolution Medicines, Inc. Falls 5.28% in Regular Trading, Biotech Sector Weakness Pressures Shares
RBC Raises Price Target on Revolution Medicines to $259 From $251, Keeps Outperform Rating
MT Newswires Live  ·  10-08 19:44
RBC Raises Price Target on Revolution Medicines to $259 From $251, Keeps Outperform Rating
Will Phase 3 Trial Start Change Revolution Medicines (RVMD) Narrative
Simply Wall St.  ·  10-08 15:26
Will Phase 3 Trial Start Change Revolution Medicines (RVMD) Narrative
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
GlobeNewswire  ·  10-07 20:30
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
Movement Alert｜Revolution Medicines, Inc. Falls 5.23% in Regular Trading, Biotechnology Sector Weakness Drags Down Shares
Market Focus  ·  10-06 22:14
Movement Alert｜Revolution Medicines, Inc. Falls 5.23% in Regular Trading, Biotechnology Sector Weakness Drags Down Shares
Maintained Buy on Revolution Medicines: Strong RAS Franchise Momentum and ESMO GI 2026 Data Support Unchanged $315 Price Target
TIPRANKS  ·  10-05
Maintained Buy on Revolution Medicines: Strong RAS Franchise Momentum and ESMO GI 2026 Data Support Unchanged $315 Price Target
Revolution Medicines Starts Phase 3 Trial of Rasonque-Zoldonrasib Combo in First-Line Metastatic RAS G12D Pancreatic Cancer
Reuters  ·  10-05
Revolution Medicines Starts Phase 3 Trial of Rasonque-Zoldonrasib Combo in First-Line Metastatic RAS G12D Pancreatic Cancer
Revolution Medicines Begins Treating Patients in Phase 3 Rasolute 309 Trial Evaluating Rasonque™ (Daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic Ras G12d Pancreatic Cancer
THOMSON REUTERS  ·  10-05
Revolution Medicines Begins Treating Patients in Phase 3 Rasolute 309 Trial Evaluating Rasonque™ (Daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic Ras G12d Pancreatic Cancer
Revolution Medicines, Inc. : Leerink Partners Resumes Coverage with Outperform Rating; Price Target $288
THOMSON REUTERS  ·  10-05
Revolution Medicines, Inc. : Leerink Partners Resumes Coverage with Outperform Rating; Price Target $288
Revolution Medicines Chief Development Officer Alan B. Sandler Disposes of USD 1,264,082 in Common Shares
Reuters  ·  10-02
Revolution Medicines Chief Development Officer Alan B. Sandler Disposes of USD 1,264,082 in Common Shares
Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Sells USD 743,436 in Common Shares
Reuters  ·  09-29
Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Sells USD 743,436 in Common Shares
Revolution Medicines Price Target Announced at $318.00/Share by Brookline Capital
Dow Jones  ·  09-29
Revolution Medicines Price Target Announced at $318.00/Share by Brookline Capital
Buy Rating Reiterated on Revolution Medicines as KRAS G12D Lead Strengthens; $315 Price Target Maintained
TIPRANKS  ·  09-29
Buy Rating Reiterated on Revolution Medicines as KRAS G12D Lead Strengthens; $315 Price Target Maintained
Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says
MT Newswires Live  ·  09-28
Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says
Bernstein Sticks to Their Hold Rating for Revolution Medicines (RVMD)
TIPRANKS  ·  09-26
Bernstein Sticks to Their Hold Rating for Revolution Medicines (RVMD)
Movement Alert｜Revolution Medicines, Inc. Rises 5.06% in Regular Trading, Multiple Banks Raise Price Targets Amid FDA Breakthrough Therapy Designation
Market Focus  ·  09-25
Movement Alert｜Revolution Medicines, Inc. Rises 5.06% in Regular Trading, Multiple Banks Raise Price Targets Amid FDA Breakthrough Therapy Designation

Introduction

Company Name.
Revolution Medicines, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Issue price:
--